BTG is now a part of Boston Scientific. Boston Scientific expects to complete the sale of its global embolic microspheres portfolio to Varian Medical Systems, in due course, a transaction entered into in … Explore our breakthrough products that make a … Boston Scientific (NYSE:BSX) has completed the acquisition of BTG plc (OTCPK:BTGGF). Boston Scientific said Monday its approximately $4.2 billion acquisition of U.K. interventional medicine company BTG, first announced last November, is complete. "Upon the effectiveness of the scheme of arrangement, BTG became a wholly-owned subsidiary of Boston Scientific, and BTG shares no longer trade on the London Stock Exchange. BTG develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. Under the terms of the previously announced transaction, holders of BTG common shares will receive 840 pence in cash per share.This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the financial impact of the BTG transaction, the closing of the divestiture of our microspheres business, our business plans, regulatory approvals, product development and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The transaction is expected to be immaterial to adjusted earnings per share in 2019 as a result of the BTG transaction closing later than originally anticipated, the divestiture of the Boston Scientific embolic microspheres portfolio, and the treatment of the licensing business as an asset for accounting purposes and its intended divestiture. "The addition of the BTG Interventional Medicine portfolio reinforces our category leadership strategy and enables us to offer best-in-class technologies, unparalleled clinical evidence and a strengthened commercial infrastructure to support physicians treating some of the most challenging diseases impacting patient health around the world," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.
Jeddah Meaning In Arabic, Synonyms For Says In Writing, Cher Costume Diy, The Forest Rabbit Trap, Dueling Pianos Tampa, Monsanto History Of Agriculture, Zaryadye Park Floating Bridge, Istanbul Archaeology Museum, Nokia Care Online, Daily Pooja Mantras In Kannada, Baisakhi Wishes In Punjabi, How Old Is Kevin Mcallister, Giraffe Cleaning Jobs, Remington Products Reviews, Prosaro 250 EC Bayer, Justice Souter Citizens United, Asus Workstation Motherboard, Jollibee Near Fresno, Ca, Amd Sempron 150 Specs, Lichfield Tents Instructions, Dead Heat On A Merry-go-round Harrison Ford,
Boston Scientific BTG acquisition